Daclizumab
- Atc Codes:L04AC01
- CAS Codes:152923-56-3
- PHARMGKB ID:152923-56-3
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe (d)
Austria: Zenapax; Bulgaria: Zenapax; Germany: Zenapax; Greece: Zenapax; Ireland: Zenapax; Netherlands: Zenapax; Poland: Zenapax.
North America (d)
Canada: Zenapax; USA: Zenapax.
Latin America (d)
Argentina: Zenapax; Brazil: Zenapax; Mexico: Zenapax.
Drug combinations
Chemistry
Daclizumab: C~6394~H~9888~N~1696~O~2012~S~44~ (protein moiety). Mw: approx. 150000.01. Humanized anti-TAC monoclonal antibody comprised of four subunits, two heavy chains and two light chains. All four chains are linked via disulfide bridges. The molecule contains approximately 2% carbohydrate by weight. The antibody belongs to the IgG~1~ subclass. The DNA sequence is 90% human origin and 10% mouse origin. The humanized anti-TAC is directed to the TAC receptor or high-affinity interleukin 2 receptor. Immunoglobulin G~1~ (human-mouse monoclonal clone 1H4 γ-chain anti-human interleukin 2 receptor), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer. CAS-152923-56-3 (1997).
Pharmacologic Category
Immunosuppressive Agents; Interleukin Inhibitors. (ATC-Code: L04AC01).
Mechanism of action
Daclizumab is a chimeric monoclonal IgG antibody produced by recombinant DNA technology. It inhibits immune reactions by binding and blocking the α-chain of the interleukin-2 receptor located on the surface of activated lymphocytes.
Therapeutic use
Used adjunctively with other immunosuppressants for the prophylaxis of acute organ rejection in renal transplant.
Pregnancy and lactiation implications
IgG molecules cross the placenta. Should not be used during pregnancy unless potential benefit to the mother outweighs possible risk to the fetus. Women of childbearing potential should use contraception before, during, and for 4 months following treatment. Use with caution during lactation.
Unlabeled use
Graft vs host disease. Prevention of organ rejection after heart transplant.
Contraindications
Hypersensitivity to daclizumab or any component of the formulation.
Warnings and precautions
Anaphylaxis/hypersensitivity reactions observed on initial exposure and following re-exposure. Patients on immunosuppressive therapy are at increased risk for infectious complications and/or secondary malignancies. Increased mortality in conjunction with a standard immunosuppressive regimen.